Did you read the recent investor preso? ..From P25: (All of these will impact the share price)
* OA Phase 2b trial results released. Partnering Discussions Commence
* Release Secondary End-point data front the OA Phase 2b trial – Q1/Q2 2019
* Potential to treat to MPS patients in Australia via the SAS – Q1/Q2 CY2019
* Up to 50 ex-NFL players in the US to be treated with iPPS for OA pain
* Potential for significant media attention if treatment is successful – Q1/Q2 CY2019
* File IND for Phase 2/3 for Mucopolysaccharidosis (MPS) - Q2 CY201
* Further release of patients OA data under the TGA special access scheme
throughout 2019
* File TGA Provisional Approval to sell ZILUSOL (iPPS) in Australia
* Q2 CY2019 Ø Ross River Phase 2a (safety study) trial results release – Q2/Q3 CY2019
...to name just a few
- Forums
- ASX - By Stock
- The competition and their side effects
Did you read the recent investor preso? ..From P25: (All of...
-
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
(20min delay)
|
|||||
Last
31.5¢ |
Change
0.045(16.7%) |
Mkt cap ! $82.30M |
Open | High | Low | Value | Volume |
27.5¢ | 31.5¢ | 27.5¢ | $695.5K | 2.362M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 23243 | 31.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
32.0¢ | 46000 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 47906 | 0.245 |
3 | 82048 | 0.240 |
2 | 32293 | 0.235 |
8 | 110599 | 0.230 |
7 | 89672 | 0.225 |
Price($) | Vol. | No. |
---|---|---|
0.250 | 13363 | 1 |
0.255 | 34148 | 4 |
0.260 | 6415 | 2 |
0.270 | 19081 | 2 |
0.275 | 13636 | 2 |
Last trade - 13.38pm 22/11/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |